Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 25-year-old woman with widespread lichen planus who did not respond to multiple systemic treatments, including antihistamines, hydroxychloroquine sulfate, and corticosteroids.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

Abatacept may help some people with alopecia areata regrow hair.

This review discusses various treatment options for Alopecia Areata, focusing on both medical and psychological approaches, and reports no new clinical results.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.

This review discusses recent advances in the treatment of alopecia areata, highlighting new potential therapies like JAK inhibitors and PRP, and reports no new clinical results.

This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.

JAK inhibitors are effective for hair regrowth in severe alopecia areata.

This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.

This study reviewed evidence on biologic drugs targeting immune cells for alopecia areata, finding mixed results: some achieved case-level hair regrowth, but controlled trials often showed limited efficacy.

Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

This review discusses emerging treatments and mechanisms for alopecia, highlighting potential therapies like janus kinase inhibitors and advances in stem-cell technology, but reports no new experimental results.

This review summarizes recent research on alopecia areata, highlighting advances in targeted therapies due to improved understanding of its immunopathogenesis, though it reports no new clinical results.

This review discusses current anti-inflammatory treatment options for calcium pyrophosphate crystal deposition disease (CPPD) and highlights the lack of crystal-targeted therapies, emphasizing the need for more research to guide treatment.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

This review highlights that alopecia areata, a common type of hair loss, currently lacks preventive or curative treatments, and traditional therapies such as minoxidil and corticosteroids offer inconsistent results, necessitating patient-consensual treatment planning.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

This study found that holding abatacept infusions for four weeks or longer before elective hip or knee arthroplasty did not reduce the risk of post-operative infections or readmissions.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

Skin problems are common in Bangladesh due to arsenic, prompt treatment of diabetic foot ulcers is crucial, maternal transmission causes most neonatal herpes, treatments for pediatric vasculitis are effective, the chickenpox vaccine works, more frequent UVB therapy helps psoriasis, certain jobs increase hand dermatitis risk, monoclonal antibodies treat psoriasis well, lifestyle affects psoriasis, alefacept improves psoriasis, imiquimod cream partially clears basal cell carcinoma, and iron may not help chronic hair loss.

Treating psoriasis with UVB light three times a week is faster than twice a week, and certain medications and lifestyle factors affect psoriasis treatment outcomes.

This study highlights rapid advances in alopecia areata treatment following the identification of genetic variants associated with increased disease risk, suggesting potential for precision medicine approaches.

In this study, researchers analyzed social media data to assess the comparative safety of arthritis medications, finding increased odds of herpes zoster and perforated bowel with certain therapies. Social media posts expressed more safety concerns than favorable opinions about drug safety.

This review discusses recent adult studies on systemic lupus erythematosus treatments and explores their implications for pediatric cases, emphasizing a critical need for more pediatric-focused research.